This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Activist Shorts Austerity, Goes Long M&A

Valeant is just one example in a hotbed of M&A activity in the healthcare sector.

Recently, Pfizer (PFE) took a baby step in an ambitious plan to divest its non-drugs businesses. Meanwhile, Watson Pharmaceuticals (PFE) shares have surged on its acquisition of Actavis, and industry players Abbott Laboratories (ABT), Bristol Meyers Squibb (BMY) and Covidien (COV) have all announced split plans. Warner Chilcott (WCRX) has also recently come up as a takeover candidate, in the booming pharmaceutical M&A market, which at $14 billion in deals, is up 44% from 2011 levels as of April 26, according to ThomsonReuters data.

In first quarter earnings released on Thursday, Valeant reported earnings per share of $1.14, exceeding the average analyst estimate of 97 cents, but shares gains were muted on falling markets. Since its Biovail deal, Valeant's market cap has more than doubled to $18 billion, and it's among the top 20 drug makers by market cap, excluding biotech, with its CEO Michael Pearson intent to challenge the top 10 in coming years, according to The Wall Street Journal.

Adobe, on the other hand, is in the very early stages of an M&A-fueled transition into serving mobile and Web publishers, after cutting strategic, but premium-priced deals for Macromedia, Omniture and Day Technologies, says Ubben.

That comes as Adobe stops developing its Flash Web product, which wasn't carried on Apple's (AAPL) booming iPhone, and is facing what would seem to be existential competition in the release of HTML5. As Ubben presented Adobe, a tech icon he acknowledges has a flat performance profile like perceived PC-dinosaurs Microsoft (MSFT) and Symantec (SYMC), some shook their heads with skepticism and flashed wry smiles at Monday's summit.

Doubters aren't likely to bother a contrarian like Ubben, who devotes his time to picking turnarounds that the rest of the investing world doesn't see.

He expects that companies like Conde Nast will rely on Adobe's suite of products for the bulk of their digital publishing needs, calling analytics specialist Omniture, the company's "crown jewel," though it and Macromedia are yet to return above their cost of capital. "I'm much more tolerant of low return strategic deals than I ever have been because no one is doing it," says Ubben.

As Adobe prepares for the launch of its Creative Suite 6 and Creative Cloud later in May, Adobe's first major CS product release in years, analysts are beginning to agree with Ubben's overall thesis. "CS6 is the first major upgrade of the core applications and is best captured by one reviewer as 'it updates 10% of the functionality that is used 90% of the time,'" writes Deutsche Bank analyst Tom Ernst in a April 24 note. "HTML5 in CS and integration with tools from Omniture and Day can lead to higher adoption of its Digital Marketing products creating a virtuous circle for Adobe," notes Bank of America Merrill Lynch analyst Kash Rangan in an April 24 note.

Deutsche Bank and Bank of America Merrill Lynch rate Adobe shares a buy with $42 and $37 price targets, respectively. Overall, San Jose-based Adobe receives a consensus $35.35 price target on 12 buy recommendations, 13 holds and 3 sells, according to data compiled by Bloomberg.
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ADBE $92.17 0.00%
CBG $37.34 0.00%
VRX $87.09 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs